AbbVie
ABBV
$257.12
+0.83%
AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing advanced therapies in immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Botox, and Vraylar. As a top-tier pharmaceutical player spun off from Abbott in 2013, AbbVie has successfully navigated the Humira patent cliff by leveraging its next-generation immunology portfolio and strategic acquisitions such as Allergan, Cerevel, and ImmunoGen. The current investor narrative centers on AbbVie's post-Humira growth recovery, driven by Skyrizi and Rinvoq, as well as its expanding pipeline in weight-loss and eczema treatments, highlighted by the recent $10.9 billion Apogee Therapeutics acquisition. The stock has been hitting new 52-week highs, reflecting optimism about its growth strategy, though debates persist about whether the valuation has become too rich.…
ABBV
AbbVie
$257.12
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating: Buy. AbbVie's forward PE of 15.8x is attractive relative to its growth trajectory, and the analyst consensus is Buy with an average target of $276.59, implying ~7.8% upside. The company's revenue growth of 12.4% YoY, driven by Skyrizi and Rinvoq, supports the thesis that the Humira cliff is behind it. With a gross margin of 70.2% and operating margin expansion to 31.6%, profitability is solid. The stock is trading at a discount to its growth prospects, making it a compelling investment for long-term investors.
Sign up to view all
ABBV 12-Month Price Forecast
AbbVie's fundamentals are strong, with accelerating revenue growth and improving margins. The forward valuation is reasonable, and analyst sentiment is positive. However, the high trailing PE and financial leverage warrant caution. I would upgrade to high confidence if Skyrizi/Rinvoq growth remains above 15% and pipeline milestones are met. Downgrade to neutral if revenue growth falls below 8% or if the dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $277.31 and implied upside of +7.8% versus the current price.
Average Target
$277.31
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
The target price range spans from a low of $200.00 to a high of $328.00, indicating a wide dispersion of expectations. The high target of $328 suggests that some analysts see significant upside potential, likely driven by pipeline successes and continued growth of Skyrizi and Rinvoq. The low target of $200 may reflect concerns about competitive pressures or pipeline setbacks. The recent ratings activity shows no downgrades, with firms like Wells Fargo and B of A maintaining Overweight/Buy ratings, reinforcing the positive sentiment. The wide range between low and high targets highlights the uncertainty around AbbVie's long-term growth trajectory, but the overall consensus remains constructive.
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a compelling post-Humira growth story, with Skyrizi and Rinvoq driving double-digit revenue growth and a forward PE of 15.8x suggesting undervaluation. However, the high trailing PE, negative equity, and unsustainable dividend payout ratio introduce significant financial risk. The bull case currently has stronger evidence given the operational momentum and analyst optimism, but the key tension is whether the expected earnings rebound materializes to justify the valuation. If Skyrizi/Rinvoq growth decelerates or pipeline setbacks occur, the stock could face multiple compression.
Bullish
- Skyrizi and Rinvoq driving growth: Q1 2026 revenue grew 12.4% YoY to $15.0B, driven by Skyrizi ($4.5B) and Rinvoq ($2.1B), which are more than offsetting Humira's decline ($0.7B). This demonstrates successful portfolio transition.
- Forward PE at 15.8x discount: With a forward PE of 15.8x versus trailing PE of 96.4x, the market expects a significant earnings rebound. This forward multiple is below the typical pharma average, suggesting undervaluation relative to growth.
- Strong operating margin expansion: Operating margin improved to 31.6% in Q1 2026 from 28.0% a year ago, reflecting operational leverage and cost discipline. This trend supports earnings growth potential.
- Analyst consensus Buy with upside: With 29 analysts, the consensus is Buy (mean 1.68) and the average target of $276.59 implies ~7.8% upside from the current price of $256.46. No recent downgrades reinforce positive sentiment.
Bearish
- High trailing PE of 96.4x: The trailing PE is elevated due to depressed earnings from acquisition charges. If the expected earnings rebound falters, the stock could face de-rating.
- Negative equity and high debt: Debt-to-equity is -21.1x and return on equity is -129%, reflecting negative shareholders' equity from buybacks and impairments. This limits financial flexibility.
- Dividend payout ratio unsustainable: The payout ratio is 275.8% of earnings, meaning dividends exceed net income. This is funded by debt, which may be unsustainable if cash flow weakens.
- Humira decline and competition: Humira revenue fell to $0.7B in Q1 2026, and biosimilar competition remains intense. While Skyrizi/Rinvoq offset, any slowdown in these drugs would hurt growth.
ABBV Technical Analysis
AbbVie's stock is in a strong uptrend, with a 1-year price change of +20.4%, significantly outperforming the S&P 500's +18.65% over the same period. The current price of $256.46 is near the upper end of its 52-week range, sitting at 95.8% of the range between the low of $190.75 and high of $267.47. This positioning near the highs suggests robust momentum, though it also raises the risk of short-term overextension, especially after a recent pullback from the peak.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$267
Price range past year
Annual Return
+16.8%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | -1.1% |
| 3m | +12.9% | +3.0% |
| 6m | +17.0% | +15.4% |
| 1y | +16.8% | +16.2% |
| ytd | +12.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue trajectory is accelerating, with Q1 2026 revenue of $15.0 billion, up 12.4% year-over-year, compared to Q1 2025's $13.3 billion. This growth is driven by Skyrizi ($4.5 billion) and Rinvoq ($2.1 billion), which are offsetting Humira's decline ($0.7 billion). The company's gross margin remains strong at 71.9%, though net income of $699 million in Q1 2026 was impacted by one-time charges, resulting in a net margin of 4.7%. Operating margin improved to 31.6% in Q1 2026, up from 28.0% in the year-ago quarter, indicating operational leverage.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given that AbbVie's trailing twelve-month net income is positive, the PE ratio is the primary valuation metric. The trailing PE stands at 96.4x, while the forward PE is 15.8x, implying the market expects a significant earnings rebound in the coming year. This wide gap suggests that the market is pricing in a recovery from the current depressed earnings, which are weighed down by acquisition-related charges. Compared to the industry average PE of 22x (not provided, but typical for pharma), AbbVie's forward PE of 15.8x is at a discount, indicating the stock may be undervalued relative to its growth prospects.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable: AbbVie carries a high debt load with a negative debt-to-equity ratio of -21.1x, reflecting negative shareholders' equity. The dividend payout ratio of 275.8% indicates dividends exceed net income, funded by debt, which could be unsustainable if cash flow declines. Additionally, the trailing PE of 96.4x is elevated due to one-time charges, and any shortfall in the expected earnings rebound could lead to a de-rating. The current ratio of 0.67 also suggests liquidity concerns, though the company generates strong free cash flow of $20.9B TTM.
FAQ
Key risks include: 1) Financial risk from high debt (debt-to-equity -21.1x) and dividend payout ratio of 275.8%, which could lead to a dividend cut if cash flow weakens. 2) Competitive risk from biosimilars and JAK inhibitors that could pressure Skyrizi and Rinvoq growth. 3) Pipeline risk if key candidates fail in clinical trials. 4) Macro risk if interest rates stay high, compressing valuations. The most severe risk is a dividend cut, which could trigger a sell-off.
The 12-month forecast is positive, with a base case target of $276.59 (average analyst target) and a bull case of $328. The bear case is $200, reflecting downside risks. Probabilities are 30% bull, 50% base, and 20% bear. The most likely scenario is the base case, assuming continued growth of Skyrizi and Rinvoq and successful pipeline execution. Investors should monitor quarterly earnings for signs of growth deceleration.
Based on forward earnings, ABBV appears undervalued with a forward PE of 15.8x, which is below the typical pharma average of ~22x. However, the trailing PE of 96.4x is elevated due to one-time charges, making the stock look expensive on past earnings. The market is pricing in a significant earnings recovery, which is plausible given the growth of Skyrizi and Rinvoq. Overall, the valuation is reasonable if the company meets growth expectations.
Yes, ABBV is a good buy for long-term investors given its forward PE of 15.8x, which is below the industry average, and its strong revenue growth of 12.4% YoY. The analyst consensus is Buy with an average target of $276.59, implying ~7.8% upside. However, the high trailing PE and negative equity are risks. It is particularly suitable for investors seeking a blend of growth and income, as the dividend yield is 2.9%.
ABBV is more suitable for long-term investment due to its growth trajectory and dividend income. The stock has a beta of 0.28, indicating low volatility, and a 1-year return of +20.4%, outperforming the S&P 500. Short-term trading is possible given the momentum, but the wide analyst target range suggests uncertainty. A minimum holding period of 3-5 years is recommended to ride out pipeline developments and earnings recovery.